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Although dual antiplatelet therapy is essential for patients who undergo percutaneous coronary 
interventions, the risk of bleeding remains an unsolved problem, and there is limited information on 
the potential relationship between genetic variants and major bleeding. We analyzed the correlations 
between four major single nucleotide polymorphisms (CYP2C19, ABCB1, PON1, and P2Y12 G52T 
polymorphisms) and clinical outcomes in 4489 patients from a prospective multicenter registry. 
The primary endpoint was major bleeding, defined as a Bleeding Academic Research Consortium ≥ 3 
bleeding event. The allelic frequencies of ABCB1, PON1, and both individual and combined CYP2C19 
variants did not differ significantly between patient groups with and without major bleeding. 
However, the allelic frequency of the P2Y12 variant differed significantly between the two groups. 
Focusing on the P2Y12 G52T variant, patients in the TT group had a significantly higher rate of major 
bleeding (6.4%; adjusted hazard ratio [HR] 2.51; 95% confidence interval [CI] 1.08–5.84; p = 0.033) 
than patients in the other groups (GG [2.9%] or GT [1.9%]). Therefore, the TT variant of the P2Y12 
G52T polymorphism may be an independent predictor of major bleeding.
Trial registration: NCT02707445 (https ://clini caltr ials.gov/ct2/show/NCT02 70744 5?term=02707 
445&draw=2&rank=1).
Dual antiplatelet therapy (DAPT) is essential for reducing the occurrence of ischemic events in patients under-
going percutaneous coronary intervention (PCI)1. However, the risk of bleeding associated with DAPT remains 
an unsolved problem, especially in patients with a high bleeding risk (HBR)2. The current guidelines recom-
mend short-term DAPT for patients at HBR, although the current evidence is  insufficient3,4. A recently reported 
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consensus statement has established that customized DAPT should be considered for patients at  HBR5,6. However, 
there is a lack of studies on genetic factors that affect bleeding risk.
To address this issue, we evaluated the associations of the single nucleotide polymorphisms of four genes 
(CYP2C19, ABCB1, PON1, and P2Y12 G52T) with major bleeding; these four genes are known to be involved 
in the modulation of clopidogrel absorption, metabolic activation, and biologic  activity7–10. We evaluated these 
associations in patients who underwent PCI and DAPT over a 1-year follow-up period.
Results
Characteristics of the enrolled patients. A total of 4489 patients were enrolled in the current study. The 
mean loading dose of clopidogrel was 600 mg before the index PCI, and 93.3% of patients continued to receive 
DAPT for at least 6 months. A total of 122 (2.7%) patients showed major bleeding during the follow-up period. 
Among the patients showing major bleeding events, 99 patients (81.1%) had non-procedure-related bleeding 
and 23 patients (18.9%) had periprocedural bleeding. The rates of the individual secondary endpoints of all-
cause mortality, cardiac death, non-fatal myocardial infarction, stent thrombosis, target lesion revascularization, 
and stroke were 1.4%, 0.9%, 0.8%, 0.5%, 5.0%, and 0.6%, respectively. Patients who had major bleeding were 
more likely to be female; to be older; and to have a medical history of hypertension, diabetes mellitus, hyper-
cholesterolemia, anemia, or chronic kidney disease than patients who did not have major bleeding. The usage 
of aspirin, clopidogrel, cilostazol, proton-pump inhibitors, calcium-channel blockers, angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, and beta-blockers was similar between patients with and 
without major bleeding. However, patients who had major bleeding were less likely to receive statins and short-
term DAPT than those who did not (Table 1).
Allelic frequencies according to major bleeding. The allelic frequencies of ABCB1, PON1, and both 
the individual and combined CYP2C19 variants did not differ significantly between patients with and without 
major bleeding (Table  2). However, the allelic frequency of the P2Y12 variant differed significantly between 
patients with and without major bleeding (Table 2).
P2Y12 G52T polymorphisms. The patients were divided into three groups according to the P2Y12 G52T 
variant observed (GG, GT, and TT). The baseline characteristics of patients in all three groups showed similar 
trends, including HBR factors such as chronic kidney disease and anemia. The prevalence of the other genetic 
polymorphisms (CYP2C19, PON1, and ABCB1) did not differ among the three groups (Table 3). The number 
of treated vessels, the total number of stents, minimal stent size, length of the stent, P2Y12 reaction units, DAPT 
duration, and discharge medication were also not significantly different among the three groups (Supplementary 
Table 1).
Regarding the primary endpoint, the TT group showed the highest incidence of major bleeding compared 
to the other groups (GG vs. GT vs. TT: 2.9% vs. 1.9% vs. 6.4%, log-rank p = 0.026) (Fig. 1). However, there were 
no significant differences in the secondary endpoints (any cause mortality, cardiac death, myocardial infarction, 
stent thrombosis, target lesion revascularization, and stroke) among the groups.
Multivariate analysis for poor prognostic factors of major bleeding. In the multivariate Cox 
regression analysis for major bleeding, age (per 1-year increase; adjusted hazard ratio [HR] 1.03; 95% confidence 
interval [CI] 1.01–1.05; p = 0.004), diabetes mellitus (adjusted HR 1.45; 95% CI 1.00–2.09; p = 0.049), chronic 
kidney disease (adjusted HR 2.10; 95% CI 1.24–3.55; p = 0.006), anemia (adjusted HR 4.20; 95% CI 2.79–6.34; 
p < 0.001), and the TT variant (adjusted HR 2.51; 95% CI 1.08–5.84; p = 0.033) were found to be poor prognostic 
predictors after adjusting for various factors.
Discussion
We investigated the clinical impact of genetic variants on major bleeding in patients after PCI. The two key 
findings are as follows: (1) The P2Y12 G52T polymorphism was a predictor of HBR in patients who underwent 
PCI and received DAPT; and (2) patients with the TT variant had a higher incidence of major bleeding than 
those with other variants. Furthermore, the TT variant was found to increase the bleeding risk after PCI as per 
multivariate analysis.
In a recent consensus statement from the Academic Research Consortium, several factors, such as renal 
failure, liver failure, and anemia, have been suggested as potential contributors to HBR. In patients with HBR, 
short-term DAPT is  recommended5,6; however, the current guidelines provide insufficient information regard-
ing the adjustment of the DAPT duration based on genetic information. In a recent report, the genotype-guided 
DAPT group showed a significant decrease in the incidence of bleeding events without differences in the total 
combined clinical outcomes compared to the standard-treatment DAPT  group11. These findings suggest that 
genotype-guided therapy and precision medicine may improve clinical outcomes in this patient group. In this 
study, the TT variant of the P2Y12 G52T polymorphism was an independent predictor of major bleeding. 
Multivariate analysis showed the same tendency as that reported by the current consensus on HBR in terms of 
renal disease and anemia, suggesting that a novel factor (the TT variant) should be considered to achieve better 
clinical outcomes in HBR patients.
Previous studies that evaluated the association between genetic variations and clinical outcomes have mainly 
focused on ischemic outcomes such as cardiac death, myocardial infarction, stent thrombosis, and target lesion 
 revascularization12. CYP2C19 is the most commonly studied gene, and several studies on this gene have shown 
that the gain-of-function group had a higher occurrence of bleeding events than the loss-of-function  group7,13. 
However, the prevalence of gain-of-function in Asians with the CYP2C19 variant is very low compared to that 
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Table 1.  Patients’ baseline and lesion characteristics and characteristics of in-hospital care. Data are presented 
as number (%) or mean (standard deviation). ACS acute coronary syndrome, MI myocardial infarction, PCI 
percutaneous coronary intervention, CABG coronary artery bypass graft, CVA cerebrovascular accident, CAD 
coronary artery disease, PRU P2Y12 reaction unit, DAPT dual antiplatelet therapy.
Characteristics
Total Patients without major bleeding Patients with major bleeding
p(N = 4489) (N = 4367) (N = 122)
Baseline characteristics
Male sex 3172 (70.7%) 3096 (70.9%) 76 (62.3%) 0.050
Age (years) 64.5 ± 10.7 64.3 ± 10.7 70.0 ± 10.0 < 0.001
Current smoker 1149 (25.6%) 1121 (25.7%) 28 (23.0%) 0.566
Hypertension 2824 (62.9%) 2728 (62.5%) 96 (78.7%) < 0.001
Diabetes mellitus 1468 (32.7%) 1406 (32.2%) 62 (50.8%) < 0.001
Hypercholesterolemia 1670 (37.2%) 1640 (37.6%) 30 (24.6%) 0.005
Previous MI 318 (7.1%) 306 (7.0%) 12 (9.8%) 0.307
Previous PCI 630 (14.0%) 608 (13.9%) 22 (18.0%) 0.247
Previous CABG 74 (1.6%) 70 (1.6%) 4 (3.3%) 0.283
Previous CVA 330 (7.4%) 321 (7.4%) 9 (7.4%) 1.000
Congestive heart failure 151 (3.4%) 145 (3.3%) 6 (4.9%) 0.477
Chronic kidney disease 158 (3.5%) 139 (3.2%) 19 (15.6%) < 0.001
Anemia 1071 (23.9%) 991 (22.7%) 80 (65.6%) < 0.001
Familial history of CAD 404 (9.0%) 387 (8.9%) 17 (13.9%) 0.077
Lesion characteristics
Multivessel disease 819 (18.2%) 796 (18.2%) 23 (18.9%) 0.954
Presentation with ACS 2381 (53.0%) 2311 (52.9%) 70 (57.4%) 0.378
Left anterior descending artery 2689 (59.9%) 2626 (60.1%) 63 (51.6%) 0.073
Left circumflex artery 1097 (24.4%) 1064 (24.4%) 33 (27.0%) 0.566
Right coronary artery 1488 (33.1%) 1443 (33.0%) 45 (36.9%) 0.429
Left main 184 (4.1%) 178 (4.1%) 6 (4.9%) 0.817
Presence of thrombus 213 (4.7%) 207 (4.7%) 6 (4.9%) 1.000
Thrombosuction 221 (4.9%) 217 (5.0%) 4 (3.3%) 0.523
Number of stents 0.187
1 3267 (72.8%) 3183 (72.9%) 84 (68.9%)
2 970 (21.6%) 941 (21.5%) 29 (23.8%)
3 or over 252 (5.6%) 243 (5.6%) 9 (7.3%)
Number of lesions 1.4 ± 1.0 1.4 ± 1.0 1.4 ± 1.0 0.847
Minimal stent size 3.0 ± 0.5 3.0 ± 0.5 2.9 ± 0.4 0.080
Total length of stent 32.1 ± 17.7 32.0 ± 17.6 33.2 ± 20.0 0.509
In-hospital care
Platelet function test
VerifyNow PRU 214.1 ± 76.0 213.7 ± 75.8 229.3 ± 81.8 0.025
Discharge medication
Aspirin 4467 (99.5%) 4347 (99.5%) 120 (98.4%) 0.236
Clopidogrel 4407 (98.2%) 4287 (98.2%) 120 (98.4%) 1.000
Cilostazol 316 (7.0%) 303 (6.9%) 13 (10.7%) 0.160
Proton pump inhibitor 716 (16.0%) 692 (15.8%) 24 (19.7%) 0.311
CCB 1247 (27.8%) 1219 (27.9%) 28 (23.0%) 0.269
Statin 4198 (93.5%) 4091 (93.7%) 107 (87.7%) 0.014
ARB 1533 (34.2%) 1493 (34.2%) 40 (32.8%) 0.822
ACEi 1206 (26.9%) 1166 (26.7%) 40 (32.8%) 0.164
BB 2756 (61.4%) 2688 (61.6%) 68 (55.7%) 0.227
Duration of DAPT
Total duration (days) 322.4 ± 87.4 323.4 ± 86.3 285.8 ± 114.3 < 0.001
> 6 months 4187 (93.3%) 4087 (93.6%) 100 (82.0%) < 0.001
> 12 months 3645 (81.2%) 3561 (81.5%) 84 (68.9%) 0.001
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in Caucasians with the CYP2C19  variant8,14,15. Another study on the Asian population found no association 
between the gain-of-function allele and  bleeding16. In addition, ABCB1, PON1, and P2Y12 showed a trend for 
poor clinical outcomes in terms of ischemic event. However, similar to that for CYP2C19, there was a lack of 
evidence regarding the association with poor clinical outcomes in terms of major bleeding for these  genes8,9,17,18.
Our results are similar to those of previous studies that showed that CYP2C19, ABCB1, and PON1 variants 
were not associated with significant differences in major bleeding. However, our study revealed that the P2Y12 
G52T variant had a significant relationship with major bleeding; this is important since studies on the association 
between P2Y12 and major bleeding have rarely been reported.
Fontana et al. reported that the P2Y12 G52T polymorphism is one of P2Y12 gene  polymorphisms18. To 
investigate the correlation between P2Y12 gene polymorphisms and clinical outcomes, i-T744C (rs2046934), 
C34T (rs6785930), and G52T (rs6809699) were evaluated. Studies on P2Y12 gene polymorphisms have not been 
widely conducted as compared to studies on CYP2C19 polymorphisms; this may be because the clinical impact 
of the P2Y12 gene polymorphism is relatively weaker than that of the CYP2C19  polymorphism8,12,19. A recent 
meta-analysis reported clinical outcomes according to P2Y12 gene polymorphisms. Briefly, the study found that 
P2Y12 gene polymorphisms may be associated with poor clinical outcomes (specifically, ischemic events, such as 
stent thrombosis and non-fatal myocardial infarction) and have no significant effect on bleeding. However, the 
meta-analysis evaluated these associations based on studies with relatively small patient populations. In addition, 
the bleeding analysis only included two polymorphisms (i-T744C and C34T) among the various P2Y12 receptor 
gene polymorphisms. One study reported that the P2Y12 G52T variant was associated with a higher incidence 
of major bleeding in patients with ST-elevation myocardial  infarction20.
A plausible explanation for the lack of association between P2Y12 G52T polymorphisms and major bleed-
ing in previous studies is the low prevalence of the TT variant. In this study, the prevalence of the TT variant of 
P2Y12 G52T was 2.1%; previous genetic studies have shown a similar prevalence (2–3%)8,21–24. Furthermore, 
the prevalence of the TT variant of P2Y12 G52T was similar across different ethnic populations, unlike that of 
the gain-of-function allele of  CYP2C198,25.
In G52T, the prevalence of the TT variant was relatively lower than that of the other allelic variants (i-T744C 
and C34T). In context, our findings suggest that previous studies may have underestimated the association 
between the TT variant and the risk of major bleeding owing to the low prevalence of the P2Y12 G52T variant. 
Plausible explanations of the mechanism include the following: (1) Inherited defects of the P2Y12 receptor, which 
has a potential role in platelet function, are related to platelet dysfunction and bleeding  diathesis26; and (2) there 
may be differences in ADP-induced maximal aggregation according to the P2Y12 G52T  variant21. Furthermore, 
the TT variant was related to higher ADP-induced maximal aggregation than other variants (GG or GT), which 
may have affected bleeding during the DAPT period. Thus, further studies are needed to address the mechanisms 
of major bleeding associated with the G52T variant and to confirm our results.
This study has some limitations. First, although a significantly higher occurrence of major bleeding was 
associated with the TT variant, there may be concerns about applying this result in real-world practice owing 
Table 2.  Genetic variants of four major single-nucleotide polymorphisms according to the major bleeding.
Total Patients without major bleeding Patients with major bleeding
p(N = 4489) (N = 4367) (N = 122)
CYP2C19 0.817
Normal metabolizer (*1/*1) 1682 (37.5%) 1633 (37.4%) 49 (40.2%)
Intermediate metabolizer 2171 (48.4%) 2115 (48.4%) 56 (45.9%)
*1/*2 1610 (35.9%) 1570 (36.0%) 40 (32.8%)
*1/*3 561 (12.5%) 545 (12.5%) 16 (13.1%)
Poor metabolizer 636 (14.2%) 619 (14.2%) 17 (13.9%)
*2/*2 342 (7.6%) 333 (7.6%) 9 (7.4%)
*2/*3 245 (5.5%) 238 (5.4%) 7 (5.7%)
*3/*3 49 (1.1%) 48 (1.1%) 1 (0.8%)
PON1 0.800
RR 539 (12.0%) 522 (12.0%) 17 (13.9%)
QR 2131 (47.5%) 2074 (47.5%) 57 (46.7%)
QQ 1819 (40.5%) 1771 (40.6%) 48 (39.3%)
ABCB1 0.597
CC 1824 (40.6%) 1769 (40.5%) 55 (45.1%)
CT 2060 (45.9%) 2008 (46.0%) 52 (42.6%)
TT 605 (13.5%) 590 (13.5%) 15 (12.3%)
P2Y12 G52T (rs6809699) 0.025
GG 3407 (75.9%) 3310 (75.8%) 97 (79.5%)
GT 988 (22.0%) 969 (22.2%) 19 (15.6%)
TT 94 (2.1%) 88 (2.0%) 6 (4.9%)
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to the low prevalence of the TT variant. However, this study is the largest population study to elucidate the 
correlation between the P2Y12 G52T polymorphism and major bleeding. Second, this study aimed to deter-
mine the impact of genetic variants on major bleeding after PCI. Although evaluation of the clinical impact of 
tailored DAPT was beyond the scope of this study, in the subgroup analysis of patients who received DAPT for 
3 months, there was no significant difference in the incidence of major bleeding according to the P2Y12 G52T 
variant. However, since the suggested duration of DAPT was 1 year in this study, the number of patients who 
used DAPT for 3 months was relatively small. Thus, we cannot rule out the possibility that the number of patients 
included in this subgroup analysis was insufficient to achieve adequate statistical power. Third, we evaluated 
clinical outcomes after a 1-year follow-up after PCI. Although a long-term investigation may provide insights 
into the clinical impact of P2Y12 G52T polymorphisms, major bleeding is expected to be less frequent after the 
discontinuation of DAPT after 1 year of PCI.
In conclusion, the TT variant of the P2Y12 G52T polymorphism might be an independent predictor of major 
bleeding. Therefore, short-term DAPT should be considered for patients with the TT variant to prevent major 
bleeding.
Methods
Study population. From 2012 to 2014, the GENIUS study included 5000 patients who underwent PCI for 
coronary artery disease in 20 tertiary hospitals and investigated the influence of various genotypes on coronary 
artery stenting outcomes. Among the 5000 patients, 413 patients did not meet inclusion/exclusion criteria, were 
lost to follow-up, withdrew consent, had missing genotyping results, or had missing platelet function test results. 
In addition, 98 patients with rapid metabolizers (*17) in CYP2C19 were excluded from the analysis owing to 
the confounding effects of these  substances16. Ultimately, 4489 total patients were evaluated in the current study. 
Table 3.  Baseline characteristics and genetic variants according to P2Y12 G52T gene polymorphism. Data 
are presented as number (%) or mean (standard deviation). ACS acute coronary syndrome, MI myocardial 
infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CVA cerebrovascular 
accident, CAD coronary artery disease.
P2Y12 G52T (rs6809699)
GG GT TT
p(N = 3407) (N = 988) (N = 94)
Baseline characteristics
Male sex 2410 (70.7%) 702 (71.1%) 60 (63.8%) 0.333
Age (years) 64.4 ± 10.7 64.7 ± 10.8 65.6 ± 11.8 0.379
Body mass index (kg/m2) 24.6 ± 3.1 24.6 ± 3.0 24.4 ± 2.9 0.703
Current smoker 878 (25.8%) 254 (25.7%) 17 (18.1%) 0.241
Hypertension 2126 (62.4%) 640 (64.8%) 58 (61.7%) 0.384
Diabetes mellitus 1115 (32.7%) 325 (32.9%) 28 (29.8%) 0.827
Hypercholesterolemia 1252 (36.7%) 388 (39.3%) 30 (31.9%) 0.198
Previous MI 236 (6.9%) 73 (7.4%) 9 (9.6%) 0.562
Previous PCI 476 (14.0%) 142 (14.4%) 12 (12.8%) 0.891
Previous CABG 55 (1.6%) 17 (1.7%) 2 (2.1%) 0.910
Previous CVA 246 (7.2%) 75 (7.6%) 9 (9.6%) 0.653
Congestive heart failure 106 (3.1%) 43 (4.4%) 2 (2.1%) 0.130
Chronic kidney disease 127 (3.7%) 25 (2.5%) 6 (6.4%) 0.062
Anemia 812 (23.8%) 238 (24.1%) 21 (22.3%) 0.928
Familial history of CAD 296 (8.7%) 99 (10.0%) 9 (9.6%) 0.428
Presentation with ACS 1823 (53.5%) 509 (51.5%) 49 (52.1%) 0.536
Genetic variants
CYP2C19 0.141
Normal metabolizer 1288 (37.8%) 363 (36.7%) 31 (33.0%)
Intermediate metabolizer 1658 (48.7%) 462 (46.8%) 51 (54.3%)
Poor metabolizer 461 (13.5%) 163 (16.5%) 12 (12.8%)
PON1 0.705
RR 401 (11.8%) 126 (12.8%) 12 (12.8%)
QR 1612 (47.3%) 478 (48.4%) 41 (43.6%)
QQ 1394 (40.9%) 384 (38.9%) 41 (43.6%)
ABCB1 0.930
CC 1378 (40.4%) 410 (41.5%) 36 (38.3%)
CT 1564 (45.9%) 450 (45.5%) 46 (48.9%)
TT 465 (13.6%) 128 (13.0%) 12 (12.8%)
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DAPT was recommended for 1 year (3 months minimum) after the index PCI (Fig. 2). DAPT included aspirin 
(100 mg daily) and clopidogrel (75 mg daily). No other P2Y12 inhibitors, such as ticagrelor and prasugrel, or 
anticoagulants, were prescribed after PCI. The study protocol was approved by the Institutional Review Board at 
each participating center including the Korea University Anam Hospital, Seoul, South Korea. Written informed 
consent was obtained from all patients at enrollment. This study complied with the Declaration of Helsinki and 
was registered with ClinicalTrials.gov (number NCT02707445).
Genotype and platelet reactivity. Measured single nucleotide polymorphisms (SNPs) included 
CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), ABCB1 (rs1045642), PON1 
(rs662), and P2Y12 (rs6809699). The genotype of each SNP was determined by pyrosequencing using a PSQ 
96MA Pyrosequencer (Pyrosequencing AB, Uppsala, Sweden), as previously  reported27. To measure the inhibi-
tory effect of clopidogrel on platelet reactivity, the VeriyfyNow P2Y12 assay (Accumetrics, San Diego, California, 
USA) was used. Physicians and patients were blinded to residual platelet reactivity and genotype results.
Endpoint. The primary endpoints were major bleeding, defined as Bleeding Academic Research Consortium 
(BARC) 3, 4, and 5. The secondary endpoints were any cause mortality, cardiac death, myocardial infarction, 
stent thrombosis, target lesion revascularization, and stroke.
Statistical analysis. Comparisons between groups were performed using independent Student’s t-test or 
analysis of variance (ANOVA) for continuous variables and the chi-square test for categorical variables. Post 
hoc subgroup analysis was performed based on the baseline characteristics. To estimate the effect of the clinical 
outcomes, including major bleeding, any cause mortality, cardiac death, myocardial infarction, stent thrombosis, 
target lesion revascularization, and stroke according to genetic variation, the hazard ratio (HR) was calculated 
using the Cox proportional hazard model. In the multivariate Cox regression analysis, the HR was adjusted for 
sex, age, hypertension, diabetes mellitus, previous history of myocardial infarction, previous history of PCIs, 
congestive heart failure, chronic kidney disease, current smoking status, anemia, clinical presentation to acute 
coronary syndrome (unstable angina, non-ST elevation myocardial infarction, and ST-elevation myocardial 
infarction), genetic variants (P2Y12 G52T, CYP2C19, PON1, and ABCB1), duration of DAPT, multivessel 
involvement, minimal stent size, and total stent length. Two-tailed p-values were used, and p-values of < 0.05 
were considered statistically significant. All statistical analyses were performed using the SPSS version 25.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
Figure 1.  Time-to-event curves through 1 year for major bleeding according to the P2Y12 G52T variant.
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